Acrivon therapeutics announces inducement grant under nasdaq listing rule 5635(c)(4)

Watertown, mass., oct. 16, 2024 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage precision medicine company utilizing its acrivon predictive precision proteomics (ap3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced that the company approved a grant of equity awards under its 2023 inducement plan to certain employees. the equity awards were granted in the form of stock options and have a grant date of october 15, 2024.
ACRV Ratings Summary
ACRV Quant Ranking